In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae

Robin Patel, Mark S. Rouse, Kerryl E. Piper, Franklin R. Cockerill, James M. Steckelberg

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

We report the activity of LY333328 against 35 clinical isolates of vancomycin-resistant enterococci (including organisms carrying the vanA, vanB, vanC-1, and vanC-2/3 genes, as determined by PCR), 33 clinical isolates of methicillin-resistant S. aureus, and 29 clinical isolates of high-level penicillin-resistsant S. pneumoniae. All isolates of vancomycin-resistant enterococci were inhibited by 2 μg/mL LY333328, and 8 μg/mL LY333328 was bactericidal against all isolates tested. All isolates of methicillin-resistant S. aureus were inhibited by 1 μg/mL LY333328, and 4 μg/mL LY333328 was bactericidal against all methicillin-resistant S. aureus isolates tested. All isolates of penicillin-resistant S. pneumoniae were inhibited by <0.125 μg/mL LY333328, and 0.25 μg/mL LY333328 was bactericidal against S. pneumoniae isolates tested. LY333328 is a promising new glycopeptide antimicrobial agent.

Original languageEnglish (US)
Pages (from-to)89-92
Number of pages4
JournalDiagnostic Microbiology and Infectious Disease
Volume30
Issue number2
DOIs
StatePublished - Feb 1998

Fingerprint

oritavancin
Methicillin-Resistant Staphylococcus aureus
Streptococcus pneumoniae
Penicillins
Glycopeptides
Vancomycin-Resistant Enterococci
In Vitro Techniques
Anti-Infective Agents

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy
  • Virology
  • Parasitology
  • Microbiology
  • Immunology
  • Applied Microbiology and Biotechnology

Cite this

In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae. / Patel, Robin; Rouse, Mark S.; Piper, Kerryl E.; Cockerill, Franklin R.; Steckelberg, James M.

In: Diagnostic Microbiology and Infectious Disease, Vol. 30, No. 2, 02.1998, p. 89-92.

Research output: Contribution to journalArticle

@article{20645bf08c3c4bbeaae9fa0657a980c0,
title = "In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae",
abstract = "We report the activity of LY333328 against 35 clinical isolates of vancomycin-resistant enterococci (including organisms carrying the vanA, vanB, vanC-1, and vanC-2/3 genes, as determined by PCR), 33 clinical isolates of methicillin-resistant S. aureus, and 29 clinical isolates of high-level penicillin-resistsant S. pneumoniae. All isolates of vancomycin-resistant enterococci were inhibited by 2 μg/mL LY333328, and 8 μg/mL LY333328 was bactericidal against all isolates tested. All isolates of methicillin-resistant S. aureus were inhibited by 1 μg/mL LY333328, and 4 μg/mL LY333328 was bactericidal against all methicillin-resistant S. aureus isolates tested. All isolates of penicillin-resistant S. pneumoniae were inhibited by <0.125 μg/mL LY333328, and 0.25 μg/mL LY333328 was bactericidal against S. pneumoniae isolates tested. LY333328 is a promising new glycopeptide antimicrobial agent.",
author = "Robin Patel and Rouse, {Mark S.} and Piper, {Kerryl E.} and Cockerill, {Franklin R.} and Steckelberg, {James M.}",
year = "1998",
month = "2",
doi = "10.1016/S0732-8893(97)00207-1",
language = "English (US)",
volume = "30",
pages = "89--92",
journal = "Diagnostic Microbiology and Infectious Disease",
issn = "0732-8893",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae

AU - Patel, Robin

AU - Rouse, Mark S.

AU - Piper, Kerryl E.

AU - Cockerill, Franklin R.

AU - Steckelberg, James M.

PY - 1998/2

Y1 - 1998/2

N2 - We report the activity of LY333328 against 35 clinical isolates of vancomycin-resistant enterococci (including organisms carrying the vanA, vanB, vanC-1, and vanC-2/3 genes, as determined by PCR), 33 clinical isolates of methicillin-resistant S. aureus, and 29 clinical isolates of high-level penicillin-resistsant S. pneumoniae. All isolates of vancomycin-resistant enterococci were inhibited by 2 μg/mL LY333328, and 8 μg/mL LY333328 was bactericidal against all isolates tested. All isolates of methicillin-resistant S. aureus were inhibited by 1 μg/mL LY333328, and 4 μg/mL LY333328 was bactericidal against all methicillin-resistant S. aureus isolates tested. All isolates of penicillin-resistant S. pneumoniae were inhibited by <0.125 μg/mL LY333328, and 0.25 μg/mL LY333328 was bactericidal against S. pneumoniae isolates tested. LY333328 is a promising new glycopeptide antimicrobial agent.

AB - We report the activity of LY333328 against 35 clinical isolates of vancomycin-resistant enterococci (including organisms carrying the vanA, vanB, vanC-1, and vanC-2/3 genes, as determined by PCR), 33 clinical isolates of methicillin-resistant S. aureus, and 29 clinical isolates of high-level penicillin-resistsant S. pneumoniae. All isolates of vancomycin-resistant enterococci were inhibited by 2 μg/mL LY333328, and 8 μg/mL LY333328 was bactericidal against all isolates tested. All isolates of methicillin-resistant S. aureus were inhibited by 1 μg/mL LY333328, and 4 μg/mL LY333328 was bactericidal against all methicillin-resistant S. aureus isolates tested. All isolates of penicillin-resistant S. pneumoniae were inhibited by <0.125 μg/mL LY333328, and 0.25 μg/mL LY333328 was bactericidal against S. pneumoniae isolates tested. LY333328 is a promising new glycopeptide antimicrobial agent.

UR - http://www.scopus.com/inward/record.url?scp=0031890133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031890133&partnerID=8YFLogxK

U2 - 10.1016/S0732-8893(97)00207-1

DO - 10.1016/S0732-8893(97)00207-1

M3 - Article

C2 - 9554174

AN - SCOPUS:0031890133

VL - 30

SP - 89

EP - 92

JO - Diagnostic Microbiology and Infectious Disease

JF - Diagnostic Microbiology and Infectious Disease

SN - 0732-8893

IS - 2

ER -